U.S. Markets closed

NovoCure Limited (NVCR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
74.70+0.65 (+0.88%)
At close: 04:00PM EDT
75.96 +1.26 (+1.69%)
After hours: 07:49PM EDT

NovoCure Limited

No. 4 The Forum
Second Floor Grenville Street
Saint Helier JE2 4UF
44 15 3475 6700

IndustryMedical Instruments & Supplies
Full Time Employees1,167

Key Executives

NameTitlePayExercisedYear Born
Mr. William F. DoyleExec. Chairman1.83MN/A1962
Mr. Asaf DanzigerPres, CEO & Director2.01M36.08M1966
Ms. Ashley CordovaChief Financial Officer995.2k1.97M1980
Mr. Wilhelmus C. M. GroenhuysenChief Operating Officer1.44M11.73M1958
Mr. Pritesh ShahChief Commercial Officer946.17k4.35M1978
Prof. Yoram Palti M.D., Ph.D.Founder & CTON/AN/A1938
Ms. Ingrid GoldbergVP of Investor RelationsN/AN/AN/A
Mr. Barak Ben AryeGen. CounselN/AN/AN/A
Mr. William Patrick BurkeChief HR OfficerN/AN/A1955
Dr. Ely Benaim M.D.Chief Medical OfficerN/AN/A1961
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.

Corporate Governance

NovoCure Limited’s ISS Governance QualityScore as of May 1, 2022 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.